Who are the top shareholders of the Ishita Drugs?

The top shareholders of Ishita Drugs include Umang Financial Services Limited with 9.94%, and Mahendra Girdharilal Wadhwani, the largest public shareholder at 2.15%. Individual investors hold a combined 46.89%, with no mutual funds or foreign institutional investors involved, and no pledged promoter holdings.

The top shareholders of Ishita Drugs include Umang Financial Services Limited, which holds the highest promoter stake at 9.94%. In terms of public shareholders, Mahendra Girdharilal Wadhwani is the largest, with a holding of 2.15%. Additionally, individual investors collectively hold a significant portion, accounting for 46.89% of the shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

how big is Ishita Drugs?

As of Jun 06, Ishita Drugs & Industries Ltd has a market capitalization of 24.00 Cr, classifying it as a Micro Cap company, with recent net sales of 14.99 Cr and a net profit of 0.87 Cr. Shareholder's funds are valued at 9.92 Cr, and total assets amount to 10.81 Cr.

Market Cap: As of Jun 06, Ishita Drugs & Industries Ltd has a market capitalization of 24.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, the company reported Net Sales of 14.99 Cr and a Net Profit of 0.87 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: This is based on Standalone data for the latest annual period ending in Mar 24. The Shareholder's Funds are valued at 9.92 Cr, and the Total Assets amount to 10.81 Cr.

Who are in the management team of Ishita Drugs?

As of March 2023, the management team of Ishita Drugs includes Jagdish Agrawal (Managing Director), Govind Gupta, Abha Agrawal (Non-Executive Director), Niranjan Agrawal, and Arvind Sapkal (all Directors). Only Jagdish Agrawal receives remuneration, earning Rs. 51.0 lacs, while the other directors do not.

As of March 2023, the management team of Ishita Drugs includes:<BR><BR>1. Jagdish Agrawal - Managing Director<BR>2. Govind Gupta - Director<BR>3. Abha Agrawal - Non Executive Director<BR>4. Niranjan Agrawal - Director<BR>5. Arvind Sapkal - Director<BR><BR>Jagdish Agrawal is the only member with a specified remuneration, earning Rs. 51.0 lacs, while the other directors do not receive any remuneration.

What does Ishita Drugs do?

Ishita Drugs & Industries Ltd is a micro-cap company that manufactures Active Pharmaceutical Ingredients, drug intermediates, fine chemicals, and excipients. As of March 2025, it reported net sales of 5 Cr and a market cap of Rs 24 Cr.

Overview:<BR>Ishita Drugs & Industries Ltd is a micro-cap company engaged in the manufacture of various Active Pharmaceutical Ingredients, drug intermediates, fine chemicals, and excipients within the Pharmaceuticals & Biotechnology industry.<BR><BR>History:<BR>Ishita Drugs & Industries Ltd was incorporated in February 1992 by Jagdish Agarwal. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 5 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 24 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 24.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.79<BR>- Return on Equity: 8.77%<BR>- Price to Book: 2.42<BR><BR>Contact Details:<BR>Address: Survey No 179/1 Taluka Sanand, Village Vasna-Iyava Ahmedabad Gujarat : 382170<BR>Email: ishitadrugs@vsnl.net<BR>Website: http://www.ishitadrugs.com

Has Ishita Drugs declared dividend?

No Dividend History Available

Who are the peers of the Ishita Drugs?

Ishita Drugs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Chemo Pharma Lab, Phaarmasia, Desh Rakshak, and Parmax Pharma. While Ishita Drugs has below average management and growth, its 1-year return is 23.40%, higher than Phaarmasia's -24.74% but significantly lower than Desh Rakshak's 422.50%.

Peers: The peers of Ishita Drugs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Chemo Pharma Lab, Phaarmasia, Desh Rakshak, and Parmax Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while below average management risk is found at Ishita Drugs, Phaarmasia, Desh Rakshak, and Parmax Pharma. Growth is excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while below average growth is noted for Ishita Drugs, Divi's Lab., Torrent Pharma, Phaarmasia, Desh Rakshak, and Parmax Pharma. Excellent capital structure is seen at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while good capital structure is found at Ishita Drugs, and the rest have below average or do not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Desh Rakshak at 422.50%, while the lowest is Phaarmasia at -24.74%. Ishita Drugs has a 1-year return of 23.40%, which is significantly lower than Desh Rakshak's but higher than Phaarmasia's. Additionally, Chemo Pharma Lab, Phaarmasia, and Parmax Pharma have negative six-month returns.

Is Ishita Drugs overvalued or undervalued?

As of June 2, 2025, Ishita Drugs is considered undervalued with a PE ratio of 24.07 and strong ROCE of 39.71%, outperforming peers like Sun Pharma and Divi's Lab, and has achieved a 1-year return of 23.56%, significantly higher than the Sensex's 7.60%.

As of 2 June 2025, Ishita Drugs has moved from a fair to an attractive valuation grade, indicating a shift in market perception. The company appears to be undervalued, with a PE ratio of 24.07, an EV to EBIT of 16.19, and a ROCE of 39.71%. In comparison to its peers, Ishita Drugs is more favorably positioned than Sun Pharma, which has a PE ratio of 35.25, and Divi's Lab, which shows a PE of 79.33, both of which are considered expensive.<BR><BR>Additionally, while peers like Cipla and Dr. Reddy's Labs have attractive valuations with PE ratios of 22.99 and 19.49 respectively, Ishita Drugs' strong ROCE and competitive PEG ratio of 1.47 suggest it is well-positioned for growth relative to its industry. Recent stock performance has also outpaced the Sensex, with a 1-year return of 23.56% compared to the Sensex's 7.60%, reinforcing the notion that Ishita Drugs is undervalued in the current market context.

What is the technical trend for Ishita Drugs?

As of June 3, 2025, Ishita Drugs shows a mildly bearish trend, with bearish weekly MACD and moving averages, while mixed signals from KST and Bollinger Bands suggest potential for future gains.

As of 3 June 2025, the technical trend for Ishita Drugs has changed from bearish to mildly bearish. The weekly MACD remains bearish, while the monthly MACD is mildly bearish, indicating a lack of strong upward momentum. The daily moving averages are also mildly bearish, reinforcing the current trend. The KST shows a mildly bullish stance on the weekly chart but is mildly bearish on the monthly, suggesting mixed signals. The Bollinger Bands indicate a sideways movement on the weekly timeframe but are bullish on the monthly, which could imply potential for future gains. Overall, the current technical stance is mildly bearish, driven primarily by the bearish MACD and moving averages, with some conflicting signals from the KST and Bollinger Bands.

When is the next results date for Ishita Drugs?

Ishita Drugs will announce its results on 12 August 2025.

Ishita Drugs will declare its results on 12 August 2025.

Are Ishita Drugs latest results good or bad?

Ishita Drugs' latest Q2 FY26 results are considered bad, with net sales dropping 43.15% to ₹3.07 crores and net profit declining 53.33% to ₹0.14 crores, indicating significant operational challenges despite a slight year-on-year improvement.

Ishita Drugs' latest results for Q2 FY26 indicate a significant decline in performance, which can be characterized as bad. The company reported net sales of ₹3.07 crores, a sharp decrease of 43.15% compared to the previous quarter. Similarly, net profit fell to ₹0.14 crores, down 53.33% quarter-on-quarter. <BR><BR>Additionally, key profitability metrics also deteriorated, with the operating margin declining to 6.19% and the PAT margin contracting to 4.56%. This performance reflects ongoing challenges in maintaining consistent revenue and profitability, particularly in a competitive pharmaceutical landscape. <BR><BR>While there was a slight year-on-year improvement in net sales compared to Q2 FY25, the sequential decline raises concerns about the company's operational stability and ability to generate steady cash flow. Overall, the results highlight significant operational challenges that the company is currently facing.

How has been the historical performance of Ishita Drugs?

Ishita Drugs has shown mixed historical performance, with net sales slightly decreasing to 15.00 Cr in March 2025 but profit metrics improving, including a profit after tax of 0.87 Cr and an EPS of 2.91. However, cash flow from operating activities turned negative at -3.00 Cr, indicating challenges in cash generation.

Answer:<BR>The historical performance of Ishita Drugs shows a mixed trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Ishita Drugs reported net sales of 15.00 Cr in March 2025, a slight decrease from 15.19 Cr in March 2024, but a notable increase from 12.07 Cr in March 2023. The total operating income mirrored this trend, reaching 15.00 Cr in March 2025. The company's total expenditure, excluding depreciation, was 14.00 Cr in March 2025, down from 14.28 Cr in March 2024, while the operating profit (PBDIT) increased to 1.34 Cr from 1.19 Cr in the previous year. Profit before tax also rose to 1.16 Cr in March 2025, up from 0.99 Cr in March 2024, leading to a profit after tax of 0.87 Cr, compared to 0.75 Cr in the prior year. The earnings per share (EPS) improved to 2.91 in March 2025 from 2.51 in March 2024. On the balance sheet, total assets increased to 16.30 Cr in March 2025 from 10.81 Cr in March 2024, while total liabilities also rose to 16.30 Cr, reflecting a significant increase in short-term borrowings to 3.81 Cr. The cash flow from operating activities showed a negative trend with -3.00 Cr in March 2025, down from 2.00 Cr in March 2024, indicating challenges in cash generation despite the growth in profits.

Should I buy, sell or hold Ishita Drugs?

Why is Ishita Drugs falling/rising?

As of 21-Dec, Ishita Drugs & Industries Ltd's stock price is rising to 76.00, driven by strong short-term performance and increased investor interest, despite long-term concerns such as a decline over the past year and weak fundamentals. The stock has outperformed its sector today and is trading at an attractive valuation compared to peers.

As of 21-Dec, Ishita Drugs & Industries Ltd's stock price is rising, currently at 76.00, reflecting a change of 3.93 (5.45%) upward. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 4.7% today, indicating strong relative performance. It opened with a significant gain of 5.87% and reached an intraday high of Rs 79.81, which is a 10.74% increase. Additionally, there has been a notable rise in investor participation, with delivery volume on December 17 increasing by 628.46% compared to the 5-day average, suggesting heightened interest from investors.<BR><BR>In terms of stock performance over different periods, Ishita Drugs has shown positive returns in the short term, with a 1-week increase of 5.47% and a 1-month increase of 6.29%. This contrasts with the broader market, as the Sensex has seen declines over the same periods. Furthermore, the stock is trading at a discount compared to its peers, with an attractive valuation indicated by a Price to Book Value of 2.1 and a PEG ratio of 0.8, which may attract value investors.<BR><BR>However, it is important to note that while the stock is currently rising, it has experienced a decline of 11.53% over the past year and has weak long-term fundamentals, including a low average Return on Equity (ROE) of 8.40% and poor growth metrics. Despite these long-term concerns, the immediate factors contributing to the stock's rise include strong short-term performance, increased trading volume, and favorable valuation metrics.

Which are the latest news on Ishita Drugs?